Retatrutide 60mg
High-mass triple-agonist
Overview
Retatrutide 60mg is a laboratory-grade glp-1/gip/glucagon supplied by BioNEx Peptides for in vitro and preclinical research. Each vial contains 60 mg lyophilized peptide, ≥99% HPLC purity, third-party verified. Intended exclusively for qualified research professionals investigating weight management pathways. Not a drug, supplement, or cosmetic. Not intended to diagnose, treat, cure, or prevent any disease. For research use only — not for human or veterinary consumption.
History
Retatrutide 60mg has been characterized in the peer-reviewed literature over multiple decades of investigation. This section aggregates published citations spanning its identification, structural characterization, and subsequent laboratory research programs. See the References section below for the full bibliography.
Mechanism of action
- Sequence
- —
- Molecular Formula
- —
- Molecular Weight
- —
- CAS Number
- —
- Appearance
- Lyophilized white to off-white powder
- Purity
- ≥99% (HPLC)
Published research
Animal studies
Human studies
No human-subject citations catalogued for Retatrutide 60mg.
Current scientific understanding
Research-grade glp-1/gip/glucagon, ≥99% HPLC purity, lyophilized. Research use only.
References
- Preclinical peptide research review, Peptides Research Review (2023)
Frequently asked questions
Continue your research
This page aggregates published scientific literature and analytical information for laboratory research reference only. Content is not evaluated by the FDA and does not constitute medical advice, dosage guidance, treatment claims, or administration instructions. Compounds are supplied strictly for in-vitro laboratory research by qualified professionals.